After-Hours Market Unpacked: Tech Shines, Payments Falter, and Biotech Swings

Wall Street wrapped up Thursday, August 13, 2026, on a decidedly upbeat note, with major indices basking in green. Yet, as the closing bell faded, a different story unfolded for several individual stocks in the after-hours session, painting a rather mixed picture for investors. Let's peel back the layers and see what caught traders' eyes as the evening progressed.

First up, the semiconductor equipment titan, Applied Materials (AMAT). You might raise an eyebrow here: despite absolutely smashing Wall Street's expectations for its fiscal third-quarter results and providing some pretty robust guidance for the upcoming fourth quarter, the stock, ticker AMAT, still found itself slipping a modest 2.5% in after-hours trading. Isn't that always the way? Sometimes, even fantastic news can trigger a bit of profit-taking, especially when expectations are already sky-high. The company, a true powerhouse in its field, reported a commendable 43% jump in third-quarter profit. Analysts had been eyeing an EPS of $3.39 and revenue around $9 billion, but AMAT clearly delivered above and beyond. Looking ahead, their confidence is palpable, forecasting an impressive $10.25 billion in revenue for the fourth quarter. It truly begs the question: what more could investors want?

Shifting gears to the payment processing world, dLocal (DLO) experienced a less forgiving evening, with its stock sliding 2.3%. It seems their second-quarter earnings report, unveiled after the market close, didn't quite hit the mark where it mattered most to analysts: earnings per share. While their GAAP EPS of $0.18 only missed the consensus estimate by a slim penny, that small shortfall, coupled with a notable surge in operating expenses, was enough to send shares downward. On the brighter side, revenue did manage to impress, coming in at a healthy $399.7 million, comfortably beating estimates by over $32 million. Oh, and they also secured a rather significant $150 million credit agreement, which is certainly a positive for their financial flexibility. Still, the market often fixates on that EPS number, doesn't it?

Then there’s Zentalis Pharmaceuticals (ZNTL), which unfortunately found itself in a rather sharp decline, shedding more than 10% of its value. The culprit? The biotechnology firm announced a proposed underwritten public offering, which includes both common stock and pre-funded warrants. Now, while these offerings are often necessary for companies, especially in the capital-intensive biotech sector, to raise crucial funds for research and development, they almost inevitably lead to share dilution. And dilution, as any seasoned investor knows, usually puts immediate downward pressure on a stock's price as more shares enter the market. It’s a common trade-off, but rarely a pleasant one for existing shareholders in the short term.

Zooming back out, it’s worth remembering that these after-hours jitters occurred against a backdrop of a rather bullish main trading session. The S&P 500 (SP500) truly had a day to remember, climbing 0.6% and even hitting yet another all-time trading high. The Dow (DJI) wasn't far behind, adding a respectable 0.1%, while the tech-heavy Nasdaq Composite (COMP:IND) advanced a solid 0.8%. Even the latest July producer price data, showing wholesale inflation remained unchanged month-over-month, offered a sigh of relief. So, while specific companies navigated their unique after-hours challenges, the broader market certainly showed resilience and optimism, with U.S. stock futures generally pointing higher as the day transitioned into evening.